Has Amer Kassar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $143,488 in general payments to Amer Kassar, MD across 2,106 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amer Kassar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amer Kassar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amer Kassar, MD

Endocrinology, Diabetes & Metabolism · Dekalb, ILNPI 1932208063

Payments from drug & device makers

$143,488in general payments, 2019–2025

Across 2,106 payments — averaging $68.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$23K
Dexcom, Inc.$16K
Boehringer Ingelheim$15K
Merck$12K
Xeris Pharmaceuticals, Inc.$9K
Johnson & Johnson$9K
plus $60K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	90	$22,923
Dexcom, Inc.	69	$16,050
Boehringer Ingelheim	91	$14,881
Merck	83	$11,798
Xeris Pharmaceuticals, Inc.	65	$9,267
Johnson & Johnson	25	$8,852
Lilly USA, LLC	188	$8,662
AstraZeneca	70	$8,171
Cequr Corporation	5	$5,944
Bayer	34	$5,858
Corcept Therapeutics	103	$5,305
Novo Nordisk	206	$3,015
Recordati_rare_diseases_inc.	187	$2,380
Abbott	70	$2,231
Mannkind Corporation	82	$2,064
AbbVie(2 entities)	106	$1,568
Amgen(2 entities)	94	$1,471
Medtronic(2 entities)	31	$1,381
Ascensia Diabetes Care US Inc.	29	$1,306
Insulet Corporation	53	$1,138
Zealand Pharma US, Inc.	13	$1,026
Antares Pharma, Inc.	67	$800
Tandem Diabetes Care, Inc.	22	$786
Esperion Therapeutics, Inc.	38	$667
BD	7	$498
EUSA Pharma (US) LLC	29	$495
Amneal Pharmaceuticals LLC	30	$439
BETA Bionics, Inc.	7	$397
IBSA Pharma Inc.	24	$391
Madrigal Pharmaceuticals	13	$373
Intuity Medical Inc	13	$329
Novartis	18	$296
Sequel Med Tech, LLC	7	$267
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	17	$246
Valeritas, Inc.	15	$177
Ascendis Pharma Endocrinology Inc	3	$161
Halozyme Inc	12	$145
Amarin Pharma, Inc.	9	$143
Clarus Therapeutics Inc.	9	$130
Embecta Corp.	5	$128
Shire North American Group Inc	7	$106
Optinose US, Inc.	1	$101
Currax Pharmaceuticals LLC	7	$99
Amryt Pharma Holdings Ltd	5	$97
Astellas Pharma US Inc	3	$78
Acella Pharmaceuticals, LLC	3	$61
Avvisto Therapeutics, LLC	4	$60
Takeda Pharmaceuticals U.S.A., Inc.	2	$60
Alnylam Pharmaceuticals Inc.	2	$55
Lifescan, Inc.	4	$54
Radius Health, Inc.	2	$51
Ironwood Pharmaceuticals, Inc	3	$49
Itamar Medical Inc	2	$43
Almatica Pharma LLC	3	$43
Merz Pharmaceuticals, LLC	1	$43
Companion Medical, Inc.	2	$42
Neurocrine Biosciences, Inc.	2	$40
Pfizer	2	$38
Regeneron Healthcare Solutions, Inc.	1	$30
Ultragenyx Pharmaceutical Inc.	1	$26

How this compares

$143,488 in reported general payments places this provider in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Medicare billing

Part B allowed, 2024

$462,525

Medicare patients

1,174

Services billed

5,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Dekalb

Liana BillingsSkokie$3.4M
Leon FogelfeldChicago$1.5M
Grazia AleppoChicago$1.4M
Wahid KassarChicago$884K
Anthony PickLake Forest$665K
Hiralal MaheshwariMcHenry$642K
Wenyu HuangChicago$639K
Babak PazookiJoliet$582K
Silvana PannainChicago$575K
Ammar BayrakdarEvergreen Park$517K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →